Physician profile
Sarab Alseoudi
NPI 1811956998
$22,777.47
in general payments reported to CMS, 2019-2025
63 companies · $3,615 in 2025
The $3,615 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,287 · 2020: $2,133 · 2021: $4,211 · 2022: $2,792 · 2023: $3,239 · 2024: $3,502 · 2025: $3,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,147.60 |
| Education | $208.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,120.19 | 2019-2025 | |
| Emd Serono, INC. | $1,661.77 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,584.44 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $1,448.87 | 2019-2025 | |
| Biogen, INC. | $1,420.76 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $1,084.52 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Pfizer INC. | $1,055.11 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $994.14 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $964.20 | 2021-2025 | Botox, Qulipta, Duopa |
| Genentech USA, INC. | $800.55 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Tnkase |
| Eisai INC. | $703.69 | 2019-2025 | |
| Lundbeck LLC | $689.82 | 2020-2025 | Vyepti |
| Lilly USA, LLC | $689.52 | 2019-2025 | Emgality, Kisunla, Reyvow |
| Amgen INC. | $681.76 | 2019-2025 | Uplizna |
| Celgene Corporation | $614.26 | 2020-2025 | Zeposia |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarab Alseoudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.